Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients

Table 1

Characteristics of the patients.

Characteristic	1.0 mg of Everolimus (𝑁=51)	1.5 mg of Everolimus (𝑁=56)	𝑃 value
Age (years)	61.9±10.6	59.0±11.5	0.170
Sex (% males)	84.3	82.1	0.801
Weight (kg)	81.1±12.1	79.6±12.0	0.533
Height (cm)	176±7	174±8	0.165
Primary reason for transplantation
Dilated cardiomyopathy (%)	43.1	30.4	0.228
Coronary heart disease (%)	47.1	64.3	0.082
Others (%)	9.8	5.4	0.474
Diabetes mellitus (%)	21.6	23.2	0.512
Time since transplantation (months)	76.8±61.8	80.7±60.0	0.675
Glomerular filtration rate (mL/min/1.73 m^2)	34.4±11.9	35.8±10.3	0.528
Kind of immunosuppression after conversion
CSA/EVL (%)	66.7	58.9	0.431
TAC/EVL (%)	33.3	41.7	0.431